Q4 2012 · —
Revenue$214.43M$214.43M +5.4% vs Q4 2011+2.1% vs Q3 2012
Net Income$12.79M$12.79M +180.4% vs Q4 2011−3.2% vs Q3 2012
EPS Diluted$0.46$0.46 +187.5% vs Q4 2011±0.0% vs Q3 2012
Gross Profit$132,502,000+9.7%
Operating Incomederived$18,558,000+139.5%
Operating Cash Flowderived-$3,403,000N/M
Free Cash Flowderived-$28,075,000N/M
Margins · derived
Gross margin61.8%+2.4 pt vs Q4 2011
Operating margin8.7%+4.8 pt vs Q4 2011
Net margin6.0%+3.7 pt vs Q4 2011
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q4 2012 | Q4 2011 | Q4 2010 | Q4 2009dderived from reported figures |
|---|---|---|---|---|
| Revenue | $214.43M | $203.52M | $194.13M | — |
| Net Income | $12.79M | $4.56M | $18.81M | — |
| EPS Diluted | $0.46 | $0.16 | $0.63 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Integra Lifesciences Holdings Corp · CIK 917520 · Engraved from SEC EDGAR